Insilico Medicine utilizing high-performance computing to combat aging and age-related diseases selected for NVIDIA GTC Contest Finals

The Baltimore MD informatics company is one of 12 rising star technology players that will take the stage to compete for a $100,000 prize and a shot being recognized as the most promising GPU-fueled company

SAN JOSE, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- via PRWEB - While deep learning will be the topic of many conversation at next week's 2015 GPU technology conference, one startup will talk passionately about using high-performance NVIDIA GPU technology to fight cancer, age-related diseases and aging itself.

Insilico Medicine, a bioinformatics company located at the campus of Johns Hopkins University in Baltimore, Maryland, is one of 12 most promising technology companies selected out of the initial pool of over 150 contestants to compete in the finals of high-tech company competition at one of the though-after events in Silicon Valley, NVIDIA GPU Technology Conference.

Insilico Medicine will be exhibiting at the conference from 17th to 20th of March and will present its technology to a broad audience and a panel of high-profile judges on March 18th.

"We live in a very exciting time when information technology is converging with biotechnology blurring the boundaries, lowering barriers to entry for smaller players and creating opportunities for data wizards and machine learning experts to make a real tangible difference in human health. Insilico Medicine developed a bioinformatics platform and strategy to tackle humanity's greatest challenge - aging and age-related diseases and we are thankful to NVIDIA for this opportunity to present our vision to some of the world's brightest minds in tech", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. "NVIDIA managed to reinvent itself many times over the past two decades by acquiring crème de la crème of the most ambitious and visionary IT elite and this conference is one of their tools for attracting top talent. I would like to invite some of these geniuses to join our quest to make aging obsolete", he added.

In just over one year Insilico Medicine scientists published over 17 papers in peer-reviewed academic journals, partnered with pharmaceutical companies and received the prestigious PMWC Palo Alto 2015 "Most Promising Company" award. The Science Advisory Board of Insilico Medicine, Inc is comprised of some of the world's top scientists including the 2013 Nobel Laureate, Dr. Michael Levitt, director of pediatric oncology at Johns Hopkins, Dr. Donald Small, professor of NYU, Dr. Bud Mishra, head of aging and longevity lab at MIPT, Dr. Alexey Moskalev, bioinformatics of aging and longevity researcher from Stanford Dr. Kristen Fortney, co-founder of GeneGo, Dr. Yuri Nikolsky and is chaired by the ex-principal scientist of the Human Genome Project, Dr. Charles Cantor.

"NVIDIA already enabled video games to reach the level of realism and attractiveness that comes close to and even surpasses nature. But we are unlocking the power of NVIDIA GPU to create virtual cells, tissues, bodies and even virtual populations to simulate and test the effects of hundreds of thousands of compounds and therapies and reprogram human bodies to live longer and free of disease", said Qingsong Zhu, PhD, COO of Insilico Medicine, Inc.

Insilico Medicine booth #312 can be found on the main floor of the NVIDIA GTC exhibition. Conference video is available at and conference soundtrack is available at .

About Insilico Medicine, Inc

Insilico Medicine, Inc. is a Baltimore-based company utilizing advances in genomics and big data analysis for in silico drug discovery and drug repurposing for aging and age-related diseases. The company utilizes the GeroScope(TM), OncoFinder(TM) , Pathway Cloud Intelligence(TM) and PharmAtlas(TM) packages for aging and cancer research, pursues internal drug discovery programs, and provides services to pharmaceutical companies. For more information on Insilico Medicine's use of NVIDIA GPU Technology, please visit: for conference soundtrack, please visit .

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit


Contact Data